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Cartee, Kini, and Chen S124.e2Background: Every state requires diagnosing physicians to report new cases of melanoma to its central
cancer registry. Previous regional studies and anecdotal experience suggest that few dermatologists
are cognizant of this obligation. This oversight could result in a large number of unreported melanomas
annually and, in turn, US melanoma statistics that markedly underestimate the true incidence of the disease.Objective: We sought to quantify the percentage of dermatologists who are unaware of melanoma
reporting requirements (the knowledge gap) and who are not reporting melanoma diagnoses (the practice
gap). We also sought to delineate factors predictive of reporting knowledge and behavior.Methods: A survey was administered to attendees of the Cutaneous Oncology Symposium at the 2010
American Academy of Dermatology annual meeting.Results: In all, 104 of 419 eligible attendees completed surveys (response rate 26%). Fifty percent of
respondents do not believe they are required to report melanomas and 56% do not actively report their
diagnoses to a registry. Practice duration of less than 10 years was significantly associated with both a
knowledge gap (P = .047) and practice gap (P = .056). Similarly, dermatologists who diagnosed fewer than
10 melanomas per year were more likely to possess a knowledge gap (P = .096) and a practice gap (P =
.087) than those who diagnosed more than 10.Limitations: Limitations include small sample size and low response rate.Conclusion: A majority of dermatologists are not reporting melanomas they diagnose to a cancer registry,
and half of those surveyed were not aware that diagnosing physicians are required to report melanoma.
( J Am Acad Dermatol 2011;65:S124.e1-9.)
Key words: cancer; cancer registries; cancer reporting; melanoma.Melanoma is one of the most lethal cutaneous
malignancies and the eighth most common cancer
in the United States overall.1 In 2006, according to
the US Cancer Statistics report, there were 53,919
new cases of invasive melanoma1 or at least that is
our best estimate of melanoma incidence. The US
Cancer Statistics and many other cancer statistics are
derived from central cancer registries, most typically
a combination of the Centers for Disease Control
and Prevention (CDC) National Program of Cancer
Registries (NPCR) (http://www.cdc.gov/cancer/
npcr/) and the National Cancer Institute (NCI)
Surveillance Epidemiology and End Results (SEER)
(http://seer.cancer.gov/) databases. The quality of
NPCR and SEER statistics is wholly dependent on
the completeness of ascertainment of new cancer
cases within participating cancer registries. The
NPCR sponsors and collects incidence and treat-
ment data from the central cancer registries of 45
states, the District of Columbia, Puerto Rico, and thethe Departments of Dermatology at Emory Universitya and
tlanta Veterans Affairs Medical Center.b
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ivision of Cancer Prevention and Control, Centers for Disease
ontrol and Prevention (CDC).
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data from 96% of the US population.2 SEER is less
geographically comprehensive but collects data on
cancer incidence, treatment, staging, and survival
on 28% of the US population.3 Together, NPCR and
SEER cover the entire US population. Increased
funding enables SEER registrars to more aggres-
sively scour hospital and pathology records under
their jurisdiction to maximize case ascertainment,
but underreporting by small physician practices and
pathology laboratories remains a concern. To a
greater extent than SEER, NPCR registries are
heavily reliant on passive reporting of new cancer
cases by involved clinicians, hospitals, and pathol-
ogists. As such, in all 50 states and the District of
Columbia, diagnosing physicians are required to
report new cases of most cancers including mela-
noma to their state-based cancer registry. However,
it is unclear how many physicians are aware of this
important responsibility.recommendations, or official position of the journal editors or
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reporting and reporting delay are believed to be
significant sources of inaccuracies in our current
estimates for melanoma incidence. Although it is
impossible to ever know the true incidence of any
disease, ie, it is inevitable that some cases will escape
detection much less reporting, melanoma may beCAPSULE SUMMARY
d Physicians are required by law to report
new cases of melanoma to central cancer
registries; dermatologists may be
unaware of this mandate.
d This study surveys 104 dermatologists
regarding their awareness of and
compliance with reporting requirements.
d A majority of dermatologists surveyed
are not reporting melanomas they
diagnose to a cancer registry, and half of
the respondents were not aware that
diagnosing physicians are required to
report melanoma.
d Physicians wishing to make contact with
their state registry can find more
information at http://apps.nccd.cdc.gov/
cancercontacts/npcr/contacts.asp.particularly prone to under-
reporting. Most malignancies
are still diagnosed and/or
treated in hospitals where
typically automated report-
ing systems are in place.
Melanoma is one of a small
number of reportable can-
cers that is amenable to out-
patient management in
nonhospital-based settings,
especially for thin tumors
(\1 mm in thickness) and
in situ disease. Of note, al-
though basal and squamous
cell carcinomas are also skin
cancers that are managed in
the ambulatory setting, these
are not required to be re-
ported by registries or states.
Secondly, because it is com-
monplace in many areas of
the country for dermatolo-
gists to process and interpret the histology from their
biopsy specimens within their own offices,4 signifi-
cant numbers of melanoma may be diagnosed with-
out the tissue ever flowing through a dedicated
pathology laboratory (which we presume are more
likely to report cancer diagnoses to the state cancer
registry than individual private physicians’ offices).
Even if melanoma biopsy specimens are sent to
a pathologist for review, many dermatopathology
laboratories are not hospital based. A 1997 study
showed that the proportion of melanomas
diagnosed by nonhospital-based independent pa-
thology laboratories increased substantially to 25%
during the preceding 15 years.5 This same study
reported 57% of dermatologists had used an out-of-
state pathology laboratory, most of which were not
hospital based. Many of these independent labora-
tories may not be aware of their obligation to report
cancer diagnoses to the state registry, and registry
reporting for out-of-state patients varies according to
specific state agreements. Some states have data-
sharing agreements that ensure that registries send
out-of-state cases to neighboring states, but these
agreements are not universal. Fortunately, the North
American Association of Central Cancer Registrieshas developed a model National Interstate Data
Exchange Agreement, a single agreement to replace
the multiple state-level agreements that, as of
December 2010, 11 states have signed.6 Finally,
SEER only audits the more common cancers such
as breast and prostate. Melanomas are audited by
NPCR, as of 2004, but only the cases that werediagnosed in hospital-based
laboratories are audited; non-
hospital cases are not. This
irregular auditing process
makes melanoma especially
vulnerable to incomplete and
delayed ascertainment by
registries.
We believe that there is
significant underreporting of
melanoma in this country
caused, in part, by a lack of
awareness among diagnosing
cliniciansof their obligation to
report, ie, a ‘‘knowledgegap,’’
and a paucity of actual report-
ing, ie, a ‘‘practice gap.’’ To
begin to measure the scope
of these issues, we conducted
a survey of dermatologists
attending the Cutaneous
Oncology Symposium at the
2010 American Academy ofDermatology (AAD) conference. To our knowledge,
this is the first such survey probing amultistate sample
ofUSdermatologists on their familiaritywith reporting
requirements and on reporting processes within their
practices.
METHODS
Study subjects and survey content
This study was approved by the Emory University
Institutional Review Board (IRB00035000). The sur-
vey instrument was a 2-page questionnaire, begin-
ningwith a brief 1-paragraph introduction describing
thepurpose and significanceof the research followed
by 10 questions. The first 5 questions solicited basic
demographic and practice information, including
gender, state of practice, practice setting, specialty,
and years in practice. The sixth question asked
respondents to write in the number of melanomas
diagnosed per year; melanoma in situ was explicitly
excluded. We elected to examine only the reporting
of invasive melanomas for two reasons: (1) although
melanoma in situ is a reportable diagnosis, most in
situ cancers are not routinely included in the aggre-
gate cancer statistics published by most major sour-
ces, for example, the SEER Cancer Statistics Review
Abbreviations used:
AAD: American Academy of Dermatology
CDC: Centers for Disease Control and
Prevention
CI: confidence interval
NCI: National Cancer Institute
NPCR: National Program of Cancer Registries
OR: odds ratio
SEER: Surveillance Epidemiology and End
Results
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widely accepted or consistently applied criteria for
discriminating severely dysplastic nevi from in situ
melanomas. Pathologists often resort to protracted
descriptions of equivocal tumors, labeling them with
inadequately defined terms such as ‘‘atypical mela-
nocytic proliferation’’ or ‘‘evolving melanoma in
situ.’’ As the classification and reportability of these
borderline lesionswould nodoubt beunclear tomost
respondents (as they are to the authors), we thought
more uniform results would be obtained by focusing
only on invasive melanoma. Respondents were
asked whether they interpreted their own ‘‘histology
for pigmented lesions’’ and whether they ever used
an out-of state pathology laboratory. To assess the
knowledge gap, the survey asked if the respondent
were aware of the obligation ‘‘to report new diagno-
ses of melanoma to [his/her] state cancer registry.’’
Similarly, to address the practice gap, the final ques-
tion asked the respondent if anyone in his/her
practice actually reported ‘‘melanoma diagnoses
(new or established) to a cancer registry.’’ These final
two questions had yes/no/I don’t know responses
with an additional ‘‘other, please comment’’ choice.
The survey was distributed to attendees of the
Cutaneous Oncology Symposium (henceforth re-
ferred to as the symposium) held on the morning of
Saturday, March 6, 2010, during the AAD annual
meeting in Miami, FL. All attendees were dermatol-
ogists registered for the AAD meeting. The question-
naire was distributed to each individual upon
entering the conference room. The survey was ad-
ministered anonymously and no protected health
information was collected. One of the authors (S. C.
C.) was also a speaker at the symposium. She intro-
duced the audience to the study at the beginning of
her lecture and instructed respondents to pass com-
pleted surveys to the aisle for collection. Surveys that
were completed by dermatologists outside the
United States were not included in the analyses.
Statistical analysis
All analyses were performed with software (SAS,
Version 9.1, SAS Institute, Cary, NC). Therespondents were divided into two groups, believers
or nonbelievers, based on their answer to question 9,
‘‘Do you believe that you are obligated to report new
diagnoses of melanoma to your state cancer regis-
try?’’ and as reporters or nonreporters based on the
response to the question: ‘‘Do you or does anyone in
your practice report melanoma diagnoses (new or
established) to a cancer registry?’’ ‘‘No’’ and ‘‘I don’t
know’’ responses were grouped together. Eight re-
spondents to question 9 and 5 respondents to ques-
tion 10 entered only a comment. In most cases the
comment clearly placed the respondent into the yes
or no/don’t know category and the response was
reassigned accordingly. In two equivocal cases, the
response was categorized based on the best judg-
ment of the study authors. Sensitivity analyses were
performed with and without including these 13
‘‘comment only’’ responses, and no appreciable
effect on the analysis was demonstrable.
The primary outcome variables were: (1) posses-
sion of a knowledge gap, ie, not believing that one is
obligated to report new diagnoses of melanoma; and
(2) possession of a practice gap, ie, not reporting or
knowing of anyone in their practice who reports
melanoma diagnoses to a cancer registry. The x2 tests
were used in univariate analyses to quantify the
impact of categorical variables on the two primary
outcomes. A multivariate logistic regression was
used to develop predictive models for the two
outcomes. In these models, the potential influence
of 9 variables was analyzed: (1) gender, (2) geo-
graphic region, (3) practice location, (4) practice
setting, (5) primary clinical role, (6) practice dura-
tion, (7) number of melanomas diagnosed, (8) self-
interpretation of biopsy specimens, and (9) use of
out-of-state pathology laboratories. For the purposes
of this statistical analysis, answer choices were
grouped so each variable had 3 or fewer potential
degrees of freedom. Primary clinical role was cate-
gorized as: (1) primarily nonprocedural (inclusive of
the survey answer choices: general dermatology,
pediatric dermatology, and dermatopathology); and
(2) primarily procedural (aesthetic procedural der-
matology and Mohs). Each respondent was assigned
a geographic region, based onUS Census definitions:
Northeast, South, Midwest, orWest. Practice duration
was divided into two groups: (1) 0 to 9 years, and (2)
10 or more years. Practice location was separated
into two groups: (1) metropolitan, and (2) suburban/
rural. Practice setting was separated into 3 cate-
gories: (1) solo private practice, (2) group nonhos-
pital based (group private practice and
multispecialty practice), and (3) hospital based (ac-
ademic, Department of Veterans Affairs, health main-
tenance organization, and community hospital).
Fig 1. Geographic distribution of survey respondents.
J AM ACAD DERMATOL
NOVEMBER 2011
S124.e5 Cartee, Kini, and ChenFinally, annual number of melanomas diagnosed
was categorized as: (1) 0 to 10 cases, and (2) 10 or
more cases. As this is an exploratory study, we did
not conduct a sample size calculation. Nevertheless,
to validate that our regression analysis had sufficient
power, we used the rule of thumb of 10 subjects per
independent variable. With the 9 anticipated varia-
bles, we would need 90 subjects. P less than .05 was
considered statistically significant, but an alpha of
0.10 was used as the level of significance to enter in
the multivariate model.RESULTS
Sample size and demographics
Of the 424 attendees of the symposium, 111
completed surveys for a response rate of 26%.
Seven respondents did not practice within the
United States and were excluded, leaving a final
data set of 104.
The respondent pool had a wide geographic
distribution with 30 states represented (Fig 1).
Table I shows the results of the first half of the
survey addressing basic demographics and practice
environment. The composition of this study sample
is similar to the overall AAD composition as deter-
mined by the AAD 2009 Dermatology Practice Profile
Survey, which polled 1123 academy members on
various practice characteristics.4 Our sample was
64% male with a majority practicing in a suburban or
small urban setting and 84% working in private
practice. Although one might anticipate academi-
cians being overrepresented at the symposium, they
comprised only 7% of respondents and less than the8% in the AAD at-large. Most respondents reported
their primary clinical role as general dermatology
(82%) followed byMohs micrographic surgery (12%)
and dermatopathology (3%). The Dermatology
Practice Profile Survey does not inquire into primary
clinical role specifically but does ask about com-
pleted fellowships. Paralleling our results, 12% of
academy members have completed a Mohs or pro-
cedural dermatology fellowship and 5% a dermato-
pathology fellowship. Survey respondents were on
average older, more experienced dermatologists
with over half reporting 20 or more years of practice.
Quantity of melanomas diagnosed by
respondents
Attendees at the symposium, as expected, en-
counter melanoma on a regular basis in their prac-
tice. The median number of new cases of melanoma
diagnosed annually among respondents was 10. The
mean number of annual diagnoses was 24 and was
greatly influenced by a small number of respondents
reporting heavy melanoma exposure ([100 annual
diagnoses).
Sources of melanoma underreporting
Respondents were questioned about two scenar-
ios theorized to contribute to melanoma cases’
escaping capture by the relevant state registry, the
results of which are demonstrated in Table II. Almost
one in 8 respondents performs his/her own
histologic analysis of biopsy specimens. The
Dermatology Practice Profile Survey also inquired
about dermatopathology practice and found 20% of
Table I. Demographics of survey sample with
comparison to results from 2009 American














Male 65 (64%) 61%
Female 36 (36%) 39%
Primary clinical role




Dermatopathology 3 (3%) y





0-10 21 (20%) y
11-20 30 (29%) y
$ 20 53 (51%) y
Location
Large metropolitan 40 (38%) 35%
Small metropolitan 24 (23%) z
Suburban 30 (29%) 54%
Rural 10 (10%) 10%
Setting
Solo private practice 44 (42%) 40%
Group private practice 40 (38%) 40%
Multispecialty group 7 (7%) 9%
Academic institution 7 (7%) 8%
Community hospital 3 (3%) y
HMO 2 (2%) y
Veterans Administration 1 (1%) 1%
AAD, American Academy of Dermatology; HMO, health
maintenance organization.
*2009 Dermatology Practice Profile Survey (DPPS) was
administered by AAD to random sample of 3999 academy
members with resultant respondent pool of 1123.
yNot listed as choice in comparable DPPS question or no directly
comparable survey question.
zDPPS provided only 3 choices: urban, suburban, and rural.
Table II. Results from questions 6 through 10 of
survey
Variable N Frequency (%)
No. of melanoma cases diagnosed/y
0-10 56 54
11-20 25 24
$ 21 23 22








Know to report to state registry
Yes 52 50
No/don’t know 51 50
Actually report to state registry
Yes 46 44
No/don’t know 58 56
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of slides.
Nearly one third of respondents to our survey
reported sending pathology to an out-of-state facil-
ity. If the diagnosing physician is not reporting these
cases directly, then inclusion in the proper cancer
registry is dependent on a two-step process. The out-
of-state laboratory must report the case to its state
registry, which, in turn, has the responsibility to
transmit this out-of-state case to the state cancer
registry where the patient resides. Asmore states sign
onto the National Interstate Data ExchangeAgreement described above, data sharing will be
streamlined and its impact on melanoma statistics
will diminish. However, the National Interstate Data
Exchange Agreement will not address physicians
who perform their own histologic analyses and
smaller pathology laboratories.
Assessment of knowledge and practice gap
See Table II. Only half of respondents were aware
that diagnosing physicians were required to report
new melanoma diagnoses to their state registry.
Thus, the knowledge gap for melanoma reporting
even among clinicians with a special interest in
cutaneous oncology was an astounding 50%.
Similarly, 58 respondents either do not report newly
diagnosed melanomas or are unaware how they get
reported, yielding a practice gap of 56%.
The overlap between knowledge and practice
gap was high. A total of 44% of respondents were
both unaware of a reporting requirement and did not
actively report melanoma diagnoses. In all, 39%
possessed neither a knowledge gap nor a practice
gap, whereas 13% knewmelanomas were reportable
but were not reporting them and 6% reported their
melanomas but did so without cognizance of legis-
lation mandating the practice.
Factors associated with a knowledge and
practice gap
In univariate analysis, a longer practice duration
([10 years; P = .017) and personal in-office histo-
logic evaluation (P = .0225) were significantly corre-
lated with melanoma reporting compliance. To
Table III. Results of multivariate logistic regression analyzing influence of 9 potential variables on respondent
answering no/I don’t know to either question 9 (possessing knowledge gap) or question 10 (possessing
practice gap)
Variable Knowledge gap Practice gap
Gender
Female vs male 0.83 (0.32-2.18), P =.71 1.12 (0.41-3.08), P = .83
Geographic region
North vs West 2.09 (0.42-10.55), P =.37 1.70 (0.34-9.62), P = .52
Midwest vs West 1.57 (0.30-8.26), P =.59 0.80 (0.16-4.14), P = .79
South vs West 2.74 (0.62-12.09), P = .18 1.64 (0.38-7.16, P = .51
Clinical role
Procedural vs nonprocedural 1.55 (0.35-6.89), P =.56 0.68 (0.16-3.01), P = .61
Practice duration, y
0-9 vs $ 10 3.29 (1.01-10.70), P = .047 3.30 (0.97-11.03), P = .056
Practice location
Suburban/rural vs metropolitan 1.16 (0.44-3.03), P = .76 1.02 (0.38-2.74), P = .97
Practice setting
Solo private vs hospital based 1.18 (0.26-5.33), P = .83 2.84 (0.59-13.69), P = .19
Group nonhospital vs hospital 0.89 (0.20-3.85), P = .87 1.52 (0.34-6.93), P = .59
Annual No. of melanomas diagnosed
0-10 vs $ 10 cases 2.24 (0.87-5.80), P = .096 2.36 (0.88-6.29), P = .087
Personally evaluate histology
No vs yes 3.17 (0.62-16.13), P = .17 2.93 (0.57-14.94), P = .20
Send pathology to out-of-state facility
No vs yes 1.39 (0.51-3.84), P = .52 2.14 (0.75-6.11), P = .15
Data presented are odds ratios with 95% confidence intervals in parentheses.
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would independently predict either a knowledge or
practice gap, a multivariate logistic regression anal-
ysis was undertaken (Table III). One predictive
factor achieved statistical significance, and several
additional important trends emerged. Respondents
in practice 10 years or less were significantly more
likely to be unaware of the reporting requirement
(odds ratio [OR] 3.29, 95% confidence interval [CI]
1.01-10.70, P = .047) and to fail to actually report (OR
3.30, 95% CI 0.97-11.03, P = .056). Although not quite
statistically significant, dermatologists who diag-
nosed less than 10 new melanomas over the past
year were considerably more likely to possess a
knowledge gap (OR 2.24, 95% CI 0.87-5.80, P = .096)
and a practice gap (OR 2.36, 95% CI 0.88-6.289, P =
.087) than those who diagnosed more than 10 cases
per year. We were unable to detect any correlation
between reporting behavior and the quadrant of the
country one practices, personal histologic analysis,
or use of an out-of-state pathology laboratory.
DISCUSSION
This survey of attendees of a specific dermatology
conference produced a number of important find-
ings. Most critically, the study confirmed that even
among dermatologists interested in melanoma care
there are dramatic knowledge and practice gapswhen it comes to melanoma reporting. Half of the
dermatologists surveyed were unaware of their ob-
ligation to report new diagnoses of melanoma to
their state cancer registry, and a greater percentage
were either not actively doing so or were unsure if
and how diagnosed melanomas were reported.
Our results are consistent with prior studies that
have attempted to investigate the extent of mela-
noma underreporting in specific regions.5,7-9 To our
knowledge, only one other study has examined
underreporting on a national level.10 Comparing
data from the SEER program, which is an especially
comprehensive and intensive cancer registry but
only covers 26% of the US population, to the data
in state cancer registries reporting to NPCR demon-
strated significant omissions in the latter. Although
several states have made efforts to improve reporting
since this study was published,10 more effort on the
part of registries and diagnosing physicians is war-
ranted. Not only does underreporting lead to under-
estimates of disease burden, but variations in case
ascertainment from year to year provide a false
impression of trends in true incidence, which can
have significant influence on public health
initiatives.
Reporting delay and reporting error also contrib-
ute to challenges in using inaccurate cancer registry
data, and melanoma statistics are unusually plagued
J AM ACAD DERMATOL
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1981 to 1998 revealed reporting delay was worse for
melanoma than any other cancer.11 Their statistical
models estimated that it would require 17 years for
99% of melanomas in a given year to be reported.
Reporting delay results in artificially low estimates of
cancer incidence in more recent years falsely sug-
gesting a decline over time.
We postulate that the above-detailed issues
with current melanoma statistics primarily stem
from a lack of awareness among diagnosing clini-
cians and pathologists of their obligation to report
all melanoma diagnoses to a central cancer regis-
try. Cockburn et al7 attempted to assess the extent
of the practice gap in melanoma reporting by
surveying dermatologists and dermatopathologists
in Los Angeles County and the San Francisco Bay
Area. They estimated that only 1% of melanomas
in the regional cancer registries came from physi-
cian reporting (as opposed to hospital and labo-
ratory). Only 30.8% of surveyed outpatient
dermatology clinics in Los Angeles County rou-
tinely reported melanomas. Twenty-seven pathol-
ogy laboratories did not have a reporting system
established. The survey also made clear that there
was confusion about reporting requirements, av-
enues available, and whose responsibility it was to
report cases.
Our study of a national pool of dermatologists
revealed an even larger practice gap (58%) than that
reported in California by Cockburn et al.7 The
precise impact of nonreporting by dermatologists
on melanoma statistics is not measurable but it
engenders significant concern that many cases of
melanoma go unreported annually leading, in turn,
to artificially low incidence numbers. From a policy
and public health perspective, precise measure-
ments of incidence are critical when scarce resources
are being allocated to research, screening, and
treatment efforts.
Indeed, ‘‘identifying regions or states with higher
rates of malignant melanoma to better target com-
munities for prevention messages and education
campaigns’’ is listed by the CDC as an example of
one of the specific uses of the NPCR database.12
Clearly this mission is jeopardized when reporting
practices call into question the validity of the data-
base as it relates to melanoma reporting.
The failure of clinicians to directly report most
types of cancer usually is inconsequential because
the cases are reported by the hospital-based pathol-
ogy laboratory that renders the initial histologic
diagnosis. Central cancer registries ensure auto-
mated reporting systems are in place and functioning
in the hospitals in their jurisdictions and are workingto improve nonhospital reporting. As emphasized in
the introduction, melanoma is frequently diagnosed
in a nonhospital setting and therefore more likely to
elude timely reporting to the central cancer registry.
We examined two potential sources of lost mela-
noma cases in this brief survey. First, we found that
almost one third of respondents were using out-of-
state pathology facilities. Many of these diagnoses
may not be reported to the appropriate state of
residence of the patient. We are in the process of
conducting a follow-up survey of pathologists to
investigate procedures for routing out-of-state can-
cer diagnoses to the relevant registry if any exist.
Second, a significant minority of dermatologists
surveyed (12%) interpret their own slides in-office.
However, only 25% of this subgroup also failed to
report melanomas (3% overall) so, based on this data
set, the contribution of in-office histologic analysis to
underreporting is minimal.
We attempted to identify particular demographic
or practice parameters that were predictive of non-
reporting behavior and/or ignorance of reporting
requirements. Although we would not presume to
delineate specific central registry policy initiatives,
these parameters might be useful for central regis-
tries and dermatology organizations (eg, the AAD)
to consider targeting. The results of a logistic
regression analysis highlighted a decreased proba-
bility to report among dermatologists diagnosing
fewer than 10 cases of melanoma per year.
Therefore, one target, somewhat counterintuitively,
may be those practices with a smaller concentration
of melanoma diagnoses for educational programs to
increase their capture rate. This result also offers
some reassurance because dermatologists encoun-
tering the most melanomas seem to be the most
likely to report them, thereby minimizing the cases
not captured. Of course, this finding needs to be
confirmed in a larger study, powered to test this
hypothesis. Another target population might be
dermatologists completing residency or newly in
practice because the regression analysis also re-
vealed a significantly higher likelihood of both a
knowledge and practice gap among respondents
with the fewest years in practice.
Our study has a number of limitations. The sample
size was small. It was not a true national sampling as
numerous states were not represented in the respon-
dent pool. The 26% response rate is not as high as
desired in a survey study. The survey was adminis-
tered to physicians attending a specialized mela-
noma conference, and results may not be
generalizable to the larger community of practicing
dermatologists. As with all survey-based studies,
ours potentially suffers from response, nonresponse,
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current practices as opposed to past occurrences
(with the exception of annual number of melanomas
diagnosed), recall bias can be assumed to be mini-
mal. It is conceivable that some respondents falsely
claimed to report melanomas to provide a perceived
correct answer (response bias). Further, it is indeed
likely that respondents to our survey have a greater
tendency to report melanoma than do nonrespon-
dents (nonresponse bias). Both phenomena would
tend to yield an underestimation for the practice gap
within the population we sampled.
Despite these limitations, this pilot study high-
lights that a disconcertingly high percentage of US
dermatologists are not aware that they should be
reporting new melanoma diagnoses to their state
cancer registry (the knowledge gap). Ideally, all
diagnosing physicians should report such cases
themselves. This would ensure every case is cap-
tured by a central registry. All cancer registries have
mechanisms for identifying and eliminating dupli-
cate reports of the same incident case so the possi-
bility that another entity or physician has already
reported the case should generate no concern.
However, this study makes clear that we are still a
long way from achieving the goal of universal
reporting. Some states have electronic reporting
systems and CDC has developed a World Wide
Webebased utility that routes data to a central cancer
registry (http://www.cdc.gov/cancer/npcr/tools/
registryplus/wp.htm). However, until a streamlined,
standardized, and user-friendly process for reporting
is widely adopted by stand-alone physician practices
and smaller pathology laboratories, as a short-term
goal, physicians should be encouraged to contact
their state registry to determine the easiest way for
them to report cases. Physicians may also confirm
that the pathology laboratory to which they send
their specimens routinely reports to the relevant state
registry. Although not completely fulfilling the phy-
sician reporting obligation, this initial step should
significantly reduce melanoma underreporting by
private practitioners and small independent labora-
tories. When using an out-of-state pathology facility,
the diagnosing physician should take extra care to
ensure that his/her central cancer registry has a data-
sharing plan with that facility.
Measures to reduce the knowledge gap should be
pursued in a joint effort by registries, organized
medicine, and resident training programs. Reporting
requirements should be incorporated into dermatol-
ogy and pathology curricula and could even be
tested on certifying examinations. Physicians wish-
ing to make contact with their state registry can findmore information at http://apps.nccd.cdc.gov/
cancercontacts/npcr/contacts.asp.
Our study further suggests that a majority of US
dermatologists in private practice may not be actively
reporting theirmelanomadiagnoses (thepractice gap)
and have not taken the initiative to explore whether
these cases get reported by other entities. These
behaviors may contribute significantly to melanoma
underreporting in this country, artificially lowering
incidence statistics and diminishing the perceived
morbidity impact of melanoma relative to other can-
cers. More extensive investigations into this phenom-
enon arewarranted to inform efforts by state registries
to enhance melanoma reporting compliance.
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